1H MRS and Hyperpolarised 13C MRS Assays of Pyruvate-Lactate Exchange in SW1222 Cancer Cells In Vitro

D. K. Hill1, Y. Jamin1, N. Tardif1, A-C. Wong Te Fong1, S. P. Robinson1, H. G. Parkes1, M. R. Orton1, M. O. Leach1, Y-L. Chung1, and T. R. Eykyn1,2
1Clinical Magnetic Resonance, CRUK and EPSRC Cancer Imaging Centre, Royal Marsden NHS Trust and The Institute of Cancer Research, Sutton, Surrey, United Kingdom, 2Division of Imaging Sciences, The Rayne Institute, Lambeth Wing, St Thomas Hospital, London, United Kingdom

Introduction
Signal enhancement by Dynamic Nuclear Polarisation (DNP) is revolutionising the use of 13C MRS, allowing real-time metabolic imaging both in vitro and in vivo. A major application of hyperpolarised 13C MRS is to determine the rate of pyruvate-to-lactate exchange, which has been linked with lactate dehydrogenase activity (LDH), a key metabolic enzyme that is commonly upregulated in cancer cells. We have performed a comparative study of the in vitro kinetics of this reaction in SW1222 colorectal cancer cells, employing either thermally polarised 1H MRS, as proposed by Day et al., or hyperpolarised 13C MRS under the same physiological conditions. These kinetics were also determined from Paclitaxel treated cells to assess the sensitivity of the two assays to drug mediated change in pyruvate-to-lactate exchange rates.

Methods
All MRS was performed on a Bruker 500MHz spectrometer at 37°C.

1H MRS-based assay: 100μl D2O and 100μl of a solution of 50mM [3-13C] pyruvate and 50mM unlabelled lactate (in PBS, pH 7) was mixed with a 500μl cell suspension of SW1222 cells. Proton spectra were recorded with a single scan and data acquired every 5s using a 60° flip angle and NOESY preset for water suppression.

Hyperpolarised 13C MRS-based assay: 15mg [1-13C] pyruvic acid (99% isotopically enriched) containing 15mM trityl free radical OX63 was polarised in a HyperSense® DNP polariser for 1h. The polarised sample was dissolved in 4ml aqueous buffer (50mM sodium lactate, NaOH, 1mM EDTA) resulting in a 46±3mM pyruvate solution at pH 7. 100μl of this solution was mixed with a 500μl cell suspension of SW1222 cells, during which 13C spectra were acquired every 2s using a single scan and a 10° flip angle.

Paclitaxel Treatment: Cells were incubated for 24h prior to treatment with 1μM Paclitaxel or vehicle (ethanol). NMR assays were performed 48h later.

Data analysis: Spectra were phase and base line corrected, and peaks of interest selected and integrated over the time course of the experiment. The integrals of the 1H resonances of 13C and [3-13C] pyruvate were fitted according to a two way chemical exchange model to determine forward (kd, loss of [3-13C] pyruvate) and backward (k1, gain of 13C pyruvate) rate constants. Integrals of the hyperpolarised [1-13C] resonances of pyruvate and lactate were fitted to the modified Bloch Equations for two-site exchange and normalised to pyruvate signal intensity at time t=0. Kinetic modelling was performed using Matlab.

Results and Discussion
Despite the differences in SNR (13C signal was 270±1H), the 1H assay had adequate sensitivity to dynamically monitor the decrease in [3-13C] pyruvate and increase in 13C pyruvate resonances due to pyruvate-lactate exchange (Figure 1). Forward rates (kd) obtained from both assays were highly reproducible (Table 1). The 1H assay also allowed reproducible measurement of k1 as the lactate and pyruvate curves are only influenced by reaction kinetics, and not by relaxation processes. In contrast, accurate estimation of k1 was more difficult with the hyperpolarised 13C assay because the initial condition of an empty 13C lactate pool coupled with the decay of all the signals due to relaxation, and the relative speeds of the various reaction and relaxation rates, lead to greatest uncertainty in k1 estimates.

1H and 13C assays detected comparable and significant increases in k1 when normalised to cell number following Paclitaxel treatment (Figure 2A, B). However, when normalised to protein content, there was no significant change in k1 (Figure 2C, D). This observation is consistent with the mechanism of action of Paclitaxel, which inhibits mitosis causing G2/M arrest (confirmed by cell cycle analysis), resulting in a doubling of cell protein concentration and volume with respect to controls (data not shown). Therefore, in Paclitaxel-treated cells there is likely to be an increase in the amount of LDH enzyme per cell, causing an apparent increase in k1 when normalising to cell number.

Conclusions
In this study we present a 1H MRS-based assay which enables a measurement of pyruvate-lactate exchange with results comparable to DNP, but with the advantage of also accurately probing the backward reaction. This assay may provide a more convenient alternative to the DNP assay to measure pyruvate-lactate exchange in vitro. These data also emphasise that caution should be exercised when interpreting kinetics depending on how the reaction is normalised.

Table 1. Forward (kd) and backward (k1) rate constants of pyruvate-lactate exchange. Data are in nmol s⁻¹ 10⁶ cells and represent mean±SD (n=3). Cell numbers: 37±5×10⁶, 35±2×10⁶ (1H, 13C respectively).

<table>
<thead>
<tr>
<th>Assay</th>
<th>1H</th>
<th>13C</th>
</tr>
</thead>
<tbody>
<tr>
<td>k1</td>
<td>0.50±0.07</td>
<td>0.3±0.07</td>
</tr>
<tr>
<td>kd</td>
<td>0.30±0.06</td>
<td>0.3±0.2</td>
</tr>
</tbody>
</table>

Figure 1. Real-time 1H MRS (A) and hyperpolarised 13C MRS (B) based assay of LDH activity in SW1222 cancer cells, and the corresponding time evolution of the spectral integrals (C and D). The hyperpolarised lactate signal was normalised to the initial pyruvate signal at time t=0.

Figure 2. Forward (kd) reaction rates of pyruvate-to-lactate exchange from 1H (A, C) or 13C (B, D) MRS-based assays in control and 48h Paclitaxel treated cells. A, B: k1 is normalised to cell number (Data are in nmol s⁻¹ 10⁶ cells). C, D: k1 is normalised to protein concentration (Data are in nmol s⁻¹ mg⁻¹ protein). Data represent mean±SD (n=3). Cell numbers: 25±7×10⁶, 7±1×10⁶ (1H control, treated), 31±3×10⁶, 8±1×10⁶ (13C control, treated). (*p<0.05, unpaired two-tailed Student’s t-test).


Acknowledgments. We acknowledge the support received for the CRUK and EPSRC Cancer Imaging Centre in association with the MRC and Department of Health (England) (grants C1060/A10334 and C16412/A6269), NHS funding to the NIHR Biomedical Research Centre, The Royal Society and AstraZeneca.